Ads
related to: systemic lupus erythematosus guidelines- Important Safety Info
Visit Official HCP Website
for full product information.
- Starting LUPKYNIS®
Get info and resources to help
start your patient on LUPKYNIS®.
- Safety & Efficacy Profile
View LUPKYNIS® results in clinical
trials. Adverse reaction info.
- Physician Resources
Tools for you and your practice
to help you prescribe LUPKYNIS®.
- Important Safety Info
theoxfordcenter.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Childhood-onset systemic lupus erythematosus (i.e., cSLE), also termed juvenile-onset systemic lupus erythematosus, juvenile systemic lupus erythematosus, and pediatric systemic lupus erythematosus, is a form of the chronic inflammatory and autoimmune disease, systemic lupus erythematosus (i.e., SLE), that develops in individuals up to 18 years old. [1]
Lupus, formally called systemic lupus erythematosus (SLE), is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. [1] Symptoms vary among people and may be mild to severe. [ 1 ]
Lupus erythematosus is a collection of autoimmune diseases in which the human immune system becomes hyperactive and attacks healthy tissues. [1] Symptoms of these diseases can affect many different body systems, including joints , skin , kidneys , blood cells , heart , and lungs .
Neuropsychiatric systemic lupus erythematosus or NPSLE refers to the neurological and psychiatric manifestations of systemic lupus erythematosus. SLE is a disease in which the immune system attacks the body's own cells and tissues. It can affect various organs or systems of the body.
Lupus nephritis is an inflammation of the kidneys caused by systemic lupus erythematosus (SLE) and childhood-onset systemic lupus erythematosus which is a more severe form of SLE that develops in children up to 18 years old; both are autoimmune diseases. [3] [4] It is a type of glomerulonephritis in which the glomeruli become inflamed.
Robert George Lahita is an American physician, internist and rheumatologist, best known for his research into systemic lupus erythematosus. [ 1 ] and other autoimmune diseases. He is the author of more than 16 books and 150 scientific publications in the field of autoimmunity and immuno-endocrinology and a media consultant on health-related ...
In systemic lupus erythematosus patients, BAFF is overexpressed, which may cause autoimmune B cell proliferation and survival. Belimumab binds to BAFF and prevents it from binding to B cells. Without BAFF, B cells commit suicide and no longer contribute to the autoimmune damage of systemic lupus erythematosus. [medical citation needed]
Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus. [5] [7] It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β. [medical citation needed]
Ads
related to: systemic lupus erythematosus guidelinestheoxfordcenter.com has been visited by 10K+ users in the past month